Trial Profile

A Phase 1b/2 study in TNBC evaluating LP-184 in combination regimen with the PARP inhibitor, Olaparib.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irofulven (Primary) ; Olaparib (Primary)
Indications Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

13 Aug 2025 According to Lantern Pharma media release,Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) established for LP-184
05 May 2025 According to Lantern Pharma media release, company announced the clearance of its investigational new drug Application (IND) from the U.S. Food and Drug Administration (FDA) for this trial.
31 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com